Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Saltz Tags: CORRESPONDENCE Source Type: research

Balancing Clinical Progress With Economic Sustainability: In Quest of a Courageous Solution [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Fasola, Aprile, Pinto Tags: CORRESPONDENCE Source Type: research

Bevacizumab Plus Chemotherapy Cost Effectiveness [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Bordonaro, Cordio, Uccello, Martines, Fassari Tags: CORRESPONDENCE Source Type: research

Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Messori, De Rosa, Fadda, Pani Tags: CORRESPONDENCE Source Type: research

Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Poveda, Selle, Hilpert, Reuss, Savarese, Vergote, Witteveen, Bamias, Scotto, Mitchell, Pujade-Lauraine Tags: CORRESPONDENCE Source Type: research

A Selfless Act [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Cohn Tags: Emotions of the oncologist, All Art of Oncology Articles Source Type: research

Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement [ASCO SPECIAL ARTICLES]
The American Society of Clinical Oncology (ASCO) convened a subcommittee to develop recommendations on improving the evidence base for treating older adults with cancer in response to a critical need identified by the Institute of Medicine. Older adults experience the majority of cancer diagnoses and deaths and make up the majority of cancer survivors. Older adults are also the fastest growing segment of the US population. However, the evidence base for treating this population is sparse, because older adults are underrepresented in clinical trials, and trials designed specifically for older adults are rare. The result is ...
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Hurria, Levit, Dale, Mohile, Muss, Fehrenbacher, Magnuson, Lichtman, Bruinooge, Soto-Perez-de-Celis, Tew, Postow, Cohen Tags: Clinical Trials, ASCO Guidelines, Geriatric Oncology, Quality of Care, Policy Analysis ASCO SPECIAL ARTICLES Source Type: research

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials [REVIEW ARTICLES]
Purpose The impact of a personalized cancer treatment strategy (ie, matching patients with drugs based on specific biomarkers) is still a matter of debate. Methods We reviewed phase II single-agent studies (570 studies; 32,149 patients) published between January 1, 2010, and December 31, 2012 (PubMed search). Response rate (RR), progression-free survival (PFS), and overall survival (OS) were compared for arms that used a personalized strategy versus those that did not. Results Multivariable analysis (both weighted multiple linear regression and random effects meta-regression) demonstrated that the personalized approach, ...
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Schwaederle, Zhao, Lee, Eggermont, Schilsky, Mendelsohn, Lazar, Kurzrock Tags: Clinical Trials, Cancer Biomarkers, Gene Expression and Profiling REVIEW ARTICLES Source Type: research

Outcomes of Prognostic Disclosure: Associations With Prognostic Understanding, Distress, and Relationship With Physician Among Patients With Advanced Cancer [Palliative and Supportive Care]
Conclusion Prognostic disclosures are associated with more realistic patient expectations of LE, without decrements to their emotional well-being or the patient-physician relationship. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Enzinger, Zhang, Schrag, Prigerson Tags: End of Life, Outcomes Research, Palliative Care Palliative and Supportive Care Source Type: research

Racial/Ethnic Differences in Inpatient Palliative Care Consultation for Patients With Advanced Cancer [Palliative and Supportive Care]
Purpose Inpatient palliative care consultation (IPCC) may help address barriers that limit the use of hospice and the receipt of symptom-focused care for racial/ethnic minorities, yet little is known about disparities in the rates of IPCC. We evaluated the association between race/ethnicity and rates of IPCC for patients with advanced cancer. Patients and Methods Patients with metastatic cancer who were hospitalized between January 1, 2009, and December 31, 2010, at an urban academic medical center participated in the study. Patient-level multivariable logistic regression was used to evaluate the association between race/...
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Sharma, Cameron, Chmiel, Von Roenn, Szmuilowicz, Prigerson, Penedo Tags: Quality of Care, Palliative Care Palliative and Supportive Care Source Type: research

Oncologists' Experiences and Attitudes About Their Role in Philanthropy and Soliciting Donations From Grateful Patients [Health Services and Outcomes]
Purpose Physician participation in philanthropy is important to marshal resources that allow hospitals to pursue their missions, but little is known about how physicians participate and their attitudes toward participation. Methods To characterize philanthropic roles physicians play and their attitudes about participation and its ethical acceptability, medical oncologists affiliated with the 40 National Cancer Institute–designated comprehensive cancer centers were randomly sampled and surveyed to evaluate experiences and attitudes regarding participation in philanthropy at their institutions. Responses were tabulate...
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Walter, Griffith, Jagsi Tags: Ethics Health Services and Outcomes Source Type: research

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study [Breast Cancer]
Conclusion Invasive disease-free survival, but not OS, was significantly superior for patients with node-positive early BC who received the adjuvant standard schedule EC-T than for those who received the experimental ET-X regimen. Toxicity profiles differed substantially across arms. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Martin, Ruiz Simon, Ruiz Borrego, Ribelles, Rodriguez-Lescure, Munoz-Mateu, Gonzalez, Margeli Vila, Barnadas, Ramos, Del Barco Berron, Jara, Calvo, Martinez-Janez, Mendiola Fernandez, Rodriguez, Martinez de Duenas, Andres, Plazaola, de la Haba-Rodriguez, Tags: Chemotherapy Breast Cancer Source Type: research

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study [Breast Cancer]
Conclusion There are several limitations of this OS analysis, including that it was not planned in the original protocol but instead was added after time-to-progression results were analyzed, and that not all patients participated in additional OS follow-up. However, the present results suggest fulvestrant 500 mg extends OS versus anastrozole. This finding now awaits prospective confirmation in the larger phase III FALCON (Fulvestrant and Anastrozole Compared in Hormonal Therapy Naïve Advanced Breast Cancer) trial (ClinicalTrials.gov identifier: NCT01602380). (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Ellis, Llombart-Cussac, Feltl, Dewar, Jasiowka, Hewson, Rukazenkov, Robertson Tags: Hormonal Therapy Breast Cancer Source Type: research

Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer [Pediatric Oncology]
Conclusion Compared with doxorubicin, daunorubicin was less cardiotoxic among survivors of childhood cancer than most current guidelines suggest. This may have implications for follow-up guidelines. The feasibility of substitution of doxorubicin with daunorubicin in childhood cancer treatment protocols to reduce cardiotoxicity should be additionally investigated. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Feijen, Leisenring, Stratton, Ness, van der Pal, Caron, Armstrong, Green, Hudson, Oeffinger, Robison, Stovall, Kremer, Chow Tags: Long Term Survival & Late Effects Pediatric Oncology Source Type: research

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model [Hematologic Malignancy]
Conclusion To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic index, may be useful to stratify advanced-stage patients. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Scarisbrick, Prince, Vermeer, Quaglino, Horwitz, Porcu, Stadler, Wood, Beylot-Barry, Pham-Ledard, Foss, Girardi, Bagot, Michel, Battistella, Guitart, Kuzel, Martinez-Escala, Estrach, Papadavid, Antoniou, Rigopoulos, Nikolaou, Sugaya, Miyagaki, Gniadecki, Tags: Lymphoma, Epidemiology, Diagnosis & Staging, Non-Melanoma Skin Cancer Hematologic Malignancy Source Type: research

Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis [Hematologic Malignancy]
Purpose Brentuximab vedotin, a monoclonal antibody (cAC10) conjugated to monomethyl auristatin E, targets CD30+ receptors. This phase II open-label trial was conducted to evaluate safety and efficacy in CD30+ cutaneous T-cell lymphomas. Patients and Methods Forty-eight patients with CD30+ lymphoproliferative disorders or mycosis fungoides (MF) received an infusion of 1.8 mg/kg every 21 days. Results Forty-eight evaluable patients (22 women and 26 men; median age, 59.5 years) had an overall response rate of 73% (95% CI, 60% to 86%; 35 of 48 patients) and complete response rate of 35% (95% CI, 22% to 49%; 17 of 48 patients...
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Duvic, Tetzlaff, Gangar, Clos, Sui, Talpur Tags: Clinical Trials, Lymphoma, Chemotherapy, Biologic Therapy Hematologic Malignancy Source Type: research

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project [Hematologic Malignancy]
Purpose In contrast to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, CD30 expression of malignant lymphocytes in mycosis fungoides (MF) and Sézary syndrome (SS) is quite variable. Clinical activity and safety of brentuximab vedotin, a CD30 targeting antibody-drug conjugate, was evaluated in MF and SS. Tissue and blood biomarkers of clinical response were explored. Patients and Methods In this phase II study, patients with MF or SS with negligible to 100% CD30 expression levels were treated with brentuximab vedotin (1.8 mg/kg) every 3 weeks for a maximum of sixteen doses. The primary end point was ov...
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Kim, Tavallaee, Sundram, Salva, Wood, Li, Rozati, Nagpal, Krathen, Reddy, Hoppe, Nguyen-Lin, Weng, Armstrong, Pulitzer, Advani, Horwitz Tags: Diagnosis & Staging, Chemotherapy, Biologic Therapy, Biology & Immunology Hematologic Malignancy Source Type: research

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study [Hematologic Malignancy]
Conclusion Post-transplantation survival in AL has improved, with a dramatic reduction in early post-transplantation mortality and excellent 5-year survival. The risk-benefit ratio for autotransplantation has changed, and randomized comparison with nontransplantation approaches is again warranted. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: D'Souza, Dispenzieri, Wirk, Zhang, Huang, Gertz, Kyle, Kumar, Comenzo, Peter Gale, Lazarus, Savani, Cornell, Weiss, Vogl, Freytes, Scott, Landau, Moreb, Costa, Ramanathan, Callander, Kamble, Olsson, Ganguly, Nishihori, Kindwall-Keller, Wood, Mark, Hari Tags: Myeloma Hematologic Malignancy Source Type: research

Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial [Gastrointestinal Cancer]
Purpose To report the final efficacy findings and biomarker analysis from the NO16968 trial comparing bolus fluorouracil/folinic acid (FU/FA) with capecitabine plus oxaliplatin (XELOX) in resected stage III colon cancer. Patients and Methods After curative resection, patients were randomly assigned to receive XELOX, as oxaliplatin 130 mg/m2 on day 1 and capecitabine 1,000 mg/m2 twice daily on days 1 to 14 every 3 weeks, or bolus FU/FA, as the Mayo Clinic or Roswell Park regimens, for 6 months. The primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS). Results The intention...
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Schmoll, Tabernero, Maroun, de Braud, Price, Van Cutsem, Hill, Hoersch, Rittweger, Haller Tags: Chemotherapy Gastrointestinal Cancer Source Type: research

Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer [Gastrointestinal Cancer]
Conclusion Regorafenib provides minimal incremental benefit at high incremental cost per QALY in the third-line management of metastatic colorectal cancer. The cost-effectiveness of regorafenib could be improved by the use of value-based pricing. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Goldstein, Ahmad, Chen, Ayer, Howard, Lipscomb, El-Rayes, Flowers Tags: Chemotherapy, Cost Effectiveness Gastrointestinal Cancer Source Type: research

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer [Gastrointestinal Cancer]
Purpose We investigated choice and efficacy of subsequent treatment, with special focus on second-line therapy, in the FIRE-3 trial (FOLFIRI plus cetuximab [arm A] or bevacizumab [arm B]) for patients with KRAS wild-type metastatic colorectal cancer. Patients and Methods Start of subsequent-line (second or third) therapy was defined as use of an antitumor drug that was not part of the previous regimen. We evaluated choice, duration, and efficacy of subsequent therapy and determined the impact of subsequent-line treatment on outcome of patients in FIRE-3. Results Of 592 patients in the intent-to-treat population, 414 (69....
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Modest, Stintzing, von Weikersthal, Decker, Kiani, Vehling-Kaiser, Al-Batran, Heintges, Lerchenmuller, Kahl, Seipelt, Kullmann, Stauch, Scheithauer, Held, Mohler, Jung, Kirchner, Heinemann Tags: Chemotherapy, Combined Modality, Translational Oncology Gastrointestinal Cancer Source Type: research

Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy? [Radiation Oncology]
Purpose The choice between chemotherapy alone and chemotherapy plus consolidative radiotherapy (RT) for diffuse large B-cell lymphoma (DLBCL) remains controversial. We aimed to define factors affecting treatment selection and the resulting survival outcomes. Patients and Methods Using the National Cancer Data Base, we identified 59,255 patients with stages I and II DLBCL treated with multiagent chemotherapy alone or chemotherapy plus consolidative RT between 1998 and 2012. Univariable and multivariable analyses were performed to identify sociodemographic, treatment, and tumor characteristics predictive of overall survival...
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Vargo, Gill, Balasubramani, Beriwal Tags: Radiation Oncology Source Type: research

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma [Thoracic Oncology]
Conclusion Intratumoral genetic heterogeneity was demonstrated to coexist with histologic heterogeneity in both single-driver and ALK/EGFR coaltered LADCs. Altered oncogenic drivers in spatially separated subclones of the same tumor may be different. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Cai, Lin, Wu, Li, Zhao, Zheng, Chuai, Fei, Zhou, Hirsch Tags: Translational Oncology, Cancer Biomarkers Thoracic Oncology Source Type: research

Critical Shortage of African American Medical Oncologists in the United States [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Hamel, Chapman, Malloy, Eggly, Penner, Shields, Simon, Klamerus, Schiffer, Albrecht Tags: Quality of Care COMMENTS AND CONTROVERSIES Source Type: research

CD30 As a Target for the Treatment of Cutaneous T-Cell Lymphoma [ONCOLOGY GRAND ROUNDS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Prince Tags: Oncology Grand Rounds Source Type: research

Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Bar, Parker, Dhodapkar Tags: Myeloma, Chemotherapy EDITORIALS Source Type: research

Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: O'Neil, Venook Tags: EDITORIALS Source Type: research

Combined-Modality Therapy for Early-Stage Diffuse Large B-Cell Lymphoma: Knowing When to Quit [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Longo Tags: Combined Modality EDITORIALS Source Type: research

Evolutionary Precision Medicine: A Role for Repeat Epidermal Growth Factor Receptor Analysis in ALK-Rearranged Lung Adenocarcinoma? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Birkbak, Hiley, Swanton Tags: EDITORIALS Source Type: research

Journal Honors Michael Khodadoust, MD, PhD, As Recipient of the 2015 Journal of Clinical Oncology Young Investigator Award [JCO YIA]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Tags: JCO YIA Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Intraluminal Superior Vena Cava Metastasis in a Patient With Poorly Differentiated Thyroid Carcinoma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Murphy, Schwalb, Berlangieri, Eek Tags: Diagnosis & Staging, Surgery, Radiation, Combined Modality DIAGNOSIS IN ONCOLOGY Source Type: research

Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Tags: ERRATUM Source Type: research

Reply to D. Przepiorka et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Chen, Xie, Estey Tags: CORRESPONDENCE Source Type: research

Acute Myeloid Leukemia Response Measures Other Than Complete Remission [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Przepiorka, Deisseroth, Farrell Tags: CORRESPONDENCE Source Type: research

Reply to Z. Li et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Fang, Wang, Amos, Lee Tags: CORRESPONDENCE Source Type: research

Is C-Reactive Protein a Specific Marker in Melanoma? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Li, Feng, Sun Tags: CORRESPONDENCE Source Type: research

Reply to P.G. Gavin et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Perez, Thompson, Ballman Tags: CORRESPONDENCE Source Type: research

Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Gavin, Song, Kim, Pogue-Geile, Paik Tags: CORRESPONDENCE Source Type: research

Reply to F. Tomao et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Newcomb, Passarelli Tags: CORRESPONDENCE Source Type: research

Is Endometrial Cancer Risk Reduced by Oral Bisphosphonate Use? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Tomao, Colombo, Panici Tags: CORRESPONDENCE Source Type: research

What Do You Say When She Is No Longer Living With Cancer? [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Hensley Tags: End of life issues, Emotions of the oncologist, Patient communication, All Art of Oncology Articles Source Type: research

American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility [ASCO SPECIAL ARTICLES]
The American Society of Clinical Oncology (ASCO) has long affirmed that the recognition and management of individuals with an inherited susceptibility to cancer are core elements of oncology care. ASCO released its first statement on genetic testing in 1996 and updated that statement in 2003 and 2010 in response to developments in the field. In 2014, the Cancer Prevention and Ethics Committees of ASCO commissioned another update to reflect the impact of advances in this area on oncology practice. In particular, there was an interest in addressing the opportunities and challenges arising from the application of massively pa...
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Robson, Bradbury, Arun, Domchek, Ford, Hampel, Lipkin, Syngal, Wollins, Lindor Tags: ASCO Guidelines ASCO SPECIAL ARTICLES Source Type: research

Improving Prospects for Targeting RAS [BIOLOGY OF NEOPLASIA]
RAS mutations are among the most common oncogenic drivers in human cancers, affecting nearly a third of all solid tumors and around a fifth of common myeloid malignancies, but they have evaded therapeutic interventions, despite being the focus of intense research over the last three decades. Recent discoveries lend new understanding about the structure, function, and signaling of RAS and have opened new avenues for development of much needed new therapies. We discuss the various approaches under investigation to target mutant RAS proteins. The recent development of direct RAS inhibitors specific to KRAS G12C mutations repr...
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Singh, Longo, Chabner Tags: Biology of Neoplasia, Signal Transduction, Oncogenes Source Type: research

Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study [Hematologic Malignancy]
Conclusion Our results support that de novo AML, sAML, and tAML are biologically and prognostically distinct subtypes of AML. Patients with non-MDS-sAML have dismal outcomes, independent of age and cytogenetics. Previous myeloid disorder, age, and cytogenetics are crucial determinants of outcomes and should be integrated in treatment recommendations for these patients. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Granfeldt Ostgard, Medeiros, Sengelov, Norgaard, Andersen, Dufva, Friis, Kjeldsen, Marcher, Preiss, Severinsen, Norgaard Tags: Epidemiology, Chemotherapy Hematologic Malignancy Source Type: research

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance) [Hematologic Malignancy]
Conclusion LR is more active than lenalidomide alone in recurrent FL with similar toxicity, warranting further study in B-cell non-Hodgkin lymphoma as a platform for addition of novel agents. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Leonard, Jung, Johnson, Pitcher, Bartlett, Blum, Czuczman, Giguere, Cheson Tags: Biologic Therapy Hematologic Malignancy Source Type: research

Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Espanol de Investigacion en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide [Sarcomas]
Conclusion This preoperative chemotherapy is feasible and can also be proposed for selected elderly patients. Grade 3 or 4 hematologic toxicity was common, but DI was excellent. Concurrent preoperative RT is safe, although an increased rate of grade 4 thrombocytopenia and limited increase in wound complications may be observed. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Palassini, Ferrari, Verderio, De Paoli, Martin Broto, Quagliuolo, Comandone, Sangalli, Palmerini, Lopez-Pousa, De Sanctis, Bottelli, Libertini, Picci, Casali, Gronchi Tags: Surgery, Radiation, Chemotherapy, Combined Modality Sarcomas Source Type: research

Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence [Breast Cancer]
Purpose African American women are more likely to die as a result of breast cancer than white women. The influence of somatic genomic profiles on this racial disparity is unclear. We aimed to compare the racial distribution of tumor genomic characteristics and breast cancer recurrence. Methods We assessed white and African American women with stage I to III breast cancer diagnosed from 1988 to 2013 and primary tumors submitted to The Cancer Genome Atlas from 2010 to 2014. We used Cox proportional hazards models to evaluate the association of race and genetic traits with tumor recurrence. Results We investigated exome seq...
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Keenan, Moy, Mroz, Ross, Niemierko, Rocco, Isakoff, Ellisen, Bardia Tags: Epidemiology Breast Cancer Source Type: research

Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial [Breast Cancer]
This study aimed at evaluating the effects of electroacupuncture (EA) versus gabapentin (GP) for hot flashes among survivors of breast cancer, with a specific focus on the placebo and nocebo effects. Patients and Methods We conducted a randomized controlled trial involving 120 survivors of breast cancer experiencing bothersome hot flashes twice per day or greater. Participants were randomly assigned to receive 8 weeks of EA or GP once per day with validated placebo controls (sham acupuncture [SA] or placebo pills [PPs]). The primary end point was change in the hot flash composite score (HFCS) between SA and PP at week 8, ...
Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Mao, Bowman, Xie, Bruner, DeMichele, Farrar Tags: Clinical Trials, Menopausal Symptoms, Complementary & Alternative Medicine Breast Cancer Source Type: research